RE: Price7 Jul 2020 15:37
Read the RNS dated June 19 : The answers are all there. The placing has been done, it was oversubscribed.
The OO was a sweetener for existing share holders to get some more shares at the discounted price based on the SP of 55p which was the price the day before the OO . Any money raised via the OO is a 'bonus' for the company . They are giving you a chance to buy at the same price as the II. did in the placing 40p
Here is the prospectus : The last page has all the deadlines etc. Tomorrow we will know the outcome of the OO, and if passed the new shares will be available on July 13.
http://www.omegadiagnostics.com/Portals/0/ODX%20Fundraising%20RNS%20%2819_06_20%29.pdf
that it has raised gross proceeds of £8 million via a heavily oversubscribed Placing and Subscription of 20,000,000 new ordinary shares of 4 pence each ("New Ordinary Shares") to both new and existing institutional investors and a number of wealth managers at an issue price of 40 pence per New Ordinary Share (the "Issue Price"
Furthermore, the Company proposes to raise up to an additional £3 million by the issue of up to 7,531,100 New Ordinary Shares pursuant to an Open Offer to Qualifying Shareholders at the Issue Price ("Open Offer", together with the Placing and Subscription the "Fundraising"). The Issue Price represents a discount of approximately 27 per cent to the closing mid-market price of 55 pence on 18 June 2020, being the latest practicable date prior to this announcement. This discount reflects the rapid rise in the Company's share price from 11 pence on 8 April 2020, immediately prior to announcement of Omega's participation in the UK Rapid Test Consortium.